Live interview with Dr. Michael Haller, TrialNet

TrialNet is an international clinical trials network of the world’s leading researchers who are exploring ways to prevent, delay and reverse progression of type 1 diabetes. The network consists of leading academic institutions, physicians, and research teams at the forefront of type 1 diabetes research.

TrialNet clinical studies explore new treatments toward delaying or preventing onset of type 1 diabetes in high risk individuals and protecting beta cells and remaining insulin production in those recently diagnosed. TrialNet also offers a unique screening test for relatives of people with type 1 diabetes to identify those at high risk for developing the disease.

TrialNet is jointly funded by the National Institute of Diabetes and Digestive and Kidney Diseases, National Institute of Allergy and Infectious Diseases, National Institute of Child Health and Human Development and National Center for Research Resources at National Institutes of Health. It is also supported by the American Diabetes Association and JDRF.

Dr. Michael Haller

Dr. Michael Haller is a pediatric endocrinologist with a passion for patient care, teaching, and research. Dr. Haller’s research focuses on predicting, preventing, and reversing type 1 diabetes through a team approach that emphasizes translating findings from the laboratory bench to the patient’s bedside in a timely manner. Dr. Haller is an active investigator in the NIH funded Type 1 Diabetes TrialNet and The Environmental Determinants of Diabetes in Youth (TEDDY) study.

Dr. Haller currently serves as the Principal Investigator (PI) for the TrialNet ATG/GCSF study funded collaboratively by the NIH, the Helmsley Trust, and Sanofi. He also serves as a co-investigator for all other TrialNet studies at the University of Florida, and as the Chair of the Clinical Implementation Committee for the international TEDDY study.

Dr. Haller has also served as the PI of studies aimed at using autologous umbilical cord blood stem cells as a potential therapy for type 1 diabetes. Dr. Haller, in collaboration with Dr. Brusko continues to explore the potential for developing cord blood based therapies. Dr. Brusko is perfecting techniques that allow for the expansion of cord blood cells that help to regulate the immune system and Dr. Haller hopes to use these cells in future clinical trials.

In 2008, Dr. Haller, and his colleagues Dr. Desmond Schatz and Dr. Mark Atkinson received the JDRF’s highest award, the Mary Tyler Moore and S.Robert Levine Excellence in Clinical Research Award, for their team approach to developing therapies for type 1 diabetes. In 2009, Dr. Haller and his colleagues received the ADA Cure Award and in 2010 Dr. Haller received the ISPAD Young Investigator Award.

Below Content Ad